Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Esperion Theraptc (NQ: ESPR )

2.040 -0.090 (-4.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Esperion Theraptc

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Report Third Quarter 2024 Financial Results on November 7
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
ESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q2 2024
ESPR stock results show that Esperion Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Report Second Quarter 2024 Financial Results on August 12
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Upcoming BTIG Biotech Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Wall Street's Top 10 Stock Calls This Week - Saturday, June 22
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of June 17-21, 2024. 
Via Talk Markets
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
Since wealth without health is utterly meaningless, investors may have some confidence with these biotech stocks to buy. 
Via InvestorPlace
3 Penny Stocks to Buy if You Want to Spend Less and Earn More
These penny stocks to buy provide a good opportunity for investors to buy low-priced stocks that provide significant growth potential. 
Via InvestorPlace
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Argan Reports Strong Earnings, Joins Geron, Planet Labs PBC And Other Big Stocks Moving Higher On Friday
Via Benzinga
Esperion to Participate in Upcoming June Investor Conferences
From Esperion Therapeutics, Inc.
Via GlobeNewswire
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Therapeutics/Otsuka Partnered Cholesterol Drug Shows Effective In Japan Study
Esperion Therapeutics and Otsuka Pharmaceutical report Phase 3 trial results for bempedoic acid in Japan, achieving significant LDL-C reduction in hypercholesterolemia patients. With no serious adverse... 
Via Benzinga
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Investor Spotlight: Companies Poised for Growth Amid Recent Developments: VTAK, ESPR, FGEN, GSUN, INBS
Via AB Newswire
ESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q1 2024
ESPR stock results show that Esperion Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.